Bill of Health

SEPTEMBER 28, 2023

By Nikhil Chaudhry and Reshma Ramachandran Earlier this month, the Department of Health and Human Services announced that it had successfully included a reasonable pricing provision in a $326M investment contract with Regeneron for development of a next generation monoclonal antibody therapy for COVID-19. pharmaceutical market.

COVID-19 205

COVID-19 COVID-19 Vaccine Pharmaceutical Industry Governance 205

Bill of Health

DECEMBER 14, 2022

Food and Drug Administration (FDA). For example, physicians and companies offering cytoplasmic and mitochondrial transfer have received Untitled Letters from the FDA. After receiving the letters, these individuals and entities have ceased to provide these techniques in the United States. using administrative law: (1) adapting the U.K.’s

FDA 205

FDA COVID-19 Vaccine COVID-19 Bioethics 205

Bill of Health

JANUARY 7, 2022

The American booster push was controversial, because the scientific evidence on the need for and effectiveness of boosters was limited, and the White House exerted an unprecedented level of pressure on the FDA and CDC’s ‘independent’ scientific review processes. Ultimately, both the FDA and CDC gave their blessing to boosters.

Public Health 339

Public Health FDA Governance COVID-19 Vaccine 339